As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
Type of study:
All subjects will receive preoperative Neo-Adjuvant Chemotherapy (NAC)treatment but only those with an incomplete response to NAC will be treated with the Preoperative experimental portion of the trial explained below.
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Contact: Richard Zellars, M.D. 410-502-1421 firstname.lastname@example.org
Contact: Shirley DiPasquale, R.N. 410-614-1598 email@example.com